Table 3. Summary of pertinent series on radiation lobectomy.
| Author | Date | Patients | Tumor types | Embolization agent | Treated lobe | Dose | # Treatment sessions | Follow-up | Degree hypertrophy |
|---|---|---|---|---|---|---|---|---|---|
| Jakobs (overlap w/Vouche) | 2008 | 10 | Mixed metastases | Glass | Right | 120 Gy (mean) | 1 | 139 days (mean) | 20.3% (mean), 17.2% (median) |
| Gaba (overlap w/Vouche) | 2009 | 20 | HCC [17], CCA [3] | Glass | Right | 175 Gy (mean), 132 Gy (median) | 1.7 | 18 months (mean) | 40% (mean) |
| Ahmadzadehfar* | 2013 | 24 | Mixed metastases | Resin | Right | N/A [activity 1.67 GBq (mean), 1.75 GBq (median)] | 1 | 44 days (mean), 36 days (median) | 47% (mean), 34% (median) |
| Edeline* | 2013 | 34 | HCC | 30 glass, 4 resin | 23 right, 11 left | 122 Gy (median) | 1 | 3 months | 38% (mean) |
| Vouche* | 2013 | 83 | HCC [67], CCA [8], mCRC [8] | Glass | Right | 112 Gy (median) | 1 | >9 months | 45% (median) |
| Theysohn* (overlap w/Goebel) | 2013 | 45 | HCC | Glass | Right | 112 Gy (mean) | 1 | 12 months | 40.1% (mean) |
| Fernandez-Ros* | 2014 | 83 | HCC [52], CCA [4], mCRC [13], 14 [other] | Resin | 66 right, 17 left | N/A | 1 | >26 weeks | 45% (mean) |
| Garlipp* | 2013 | 26 | Mixed metastases | Resin | Right | N/A [activity 1.2 GBq (mean)] | 1 | 46 days | 29% (mean), 25.3% (median) |
| Teo* | 2014 | 17 | HCC | Resin | Right | N/A | 1 | 5 months (median) | 34.2% (mean) |
| Lewandowski (overlap w/Vouche) | 2016 | 13 | HCC [10], CCA [2], mCRC [1] | Glass | Right | 154 Gy (median) | 1.4 | 40 days (median) | 30% (median) |
| Goebel | 2017 | 75 | HCC | Glass | Right | 113 Gy (mean) | 1 | 6 months | 38.9% (mean) |
| Palard | 2017 | 73 | HCC | Glass | Right | 149.9 Gy (mean) | 1 | 5.9 months (mean) | 35.4% (mean) |
| Gabr (overlap w/Vouche) | 2018 | 20 | HCC | Glass | Right | 128 Gy (median) | 1.2 | Not reported | 23.3% (median) |
*, studies included in the systematic review by Teo et al. HCC, hepatocellular carcinoma; CCA, cholangiocarcinona; mCRC, metastatic colorectal cancer.